Guan, Y.; Li, J.; Gong, X.; Zhu, H.; Li, C.; Mei, G.; Liu, X.; Pan, L.; Dai, J.; Wang, Y.;
et al. Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report. Brain Sci. 2022, 12, 471.
https://doi.org/10.3390/brainsci12040471
AMA Style
Guan Y, Li J, Gong X, Zhu H, Li C, Mei G, Liu X, Pan L, Dai J, Wang Y,
et al. Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report. Brain Sciences. 2022; 12(4):471.
https://doi.org/10.3390/brainsci12040471
Chicago/Turabian Style
Guan, Yun, Jing Li, Xiu Gong, Huaguang Zhu, Chao Li, Guanghai Mei, Xiaoxia Liu, Li Pan, Jiazhong Dai, Yang Wang,
and et al. 2022. "Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report" Brain Sciences 12, no. 4: 471.
https://doi.org/10.3390/brainsci12040471
APA Style
Guan, Y., Li, J., Gong, X., Zhu, H., Li, C., Mei, G., Liu, X., Pan, L., Dai, J., Wang, Y., Wang, E., Liu, Y., & Wang, X.
(2022). Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report. Brain Sciences, 12(4), 471.
https://doi.org/10.3390/brainsci12040471